The pharmacokinetics of 1, 10, 23.25, and 139.5 mg doses of atrasentan was assessed in a placebo-controlled, double-blind, single oral dose study in 24 healthy male subjects. Atrasentan was well tolerated. Atrasentan pharmacokinetics was linear in the 1 to 23.25 mg dose range, with some dose dependency in the highest dose group. Harmonic mean terminal half-life was similar across all dose groups (20-25 h). Apparent oral clearance was low (12 L/h) for the highest dose group compared with the other three dose groups (21-27 L/h). The apparent volume of distribution was large (approximately 6 L/kg), consistent with extensive tissue distribution.

中文翻译：

---

阿托森坦（一种内皮素-A受体拮抗剂）的单剂量药代动力学。

在安慰剂对照，双盲，单次口服剂量研究中，对24位健康男性受试者评估了1、10、23.25和139.5 mg剂量的阿曲生坦的药代动力学。阿曲生坦耐受性良好。在1至23.25 mg剂量范围内，阿曲生坦的药代动力学是线性的，在最高剂量组中有一定的剂量依赖性。所有剂量组（20-25小时）的谐波平均终末半衰期均相似。与其他三个剂量组（21-27 L / h）相比，最大剂量组的表观口腔清除率低（12 L / h）。表观分布量大（约6 L / kg），与广泛的组织分布一致。